transmembrane protein 266Genealiases: C15orf27 · HVRP1 · HsHVRP1 · hTMEM266
Q-omics provides the consensus-scored TMEM266 profile across patient tissues and cancer cell-line models. TMEM266 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, TMEM266 is differentially expressed in 11, with the highest sampling consensus in LIHC. Additionally, TMEM266 RNA expression shows 17,880 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, LIHC, and UVM as cancer lineages where TMEM266 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM266 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM266 survival associations across molecular data types. TMEM266 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM266 RNA expression–survival associations across cancer types. High TMEM266 expression shows unfavorable associations in UCEC, UVM, KIRP and DLBC, but favorable associations in HNSC and OV. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for TMEM266 RNA expression.
This table summarizes TMEM266 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for TMEM266. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM266 shows lower tumor expression in LUAD, KICH and KIRP and higher tumor expression in LIHC, COAD and BLCA. The LIHC box plot shows higher TMEM266 RNA expression in tumor versus normal tissue (log2 FC = +0.699, t-test p < 0.001).
This table shows molecular features associated with TMEM266 in patient tissues and cancer cell lines. In patient samples, TMEM266 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM266 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and LARGE_INTESTINE.
